2C-T-36, also known as 2C-T-TFM, 2,5-dimethoxy-4-(trifluoromethylsulfanyl)phenethylamine, or CYB210010, is a psychedelic drug of the phenethylamine and 2C families related to other psychedelics such as 2C-TFM, 2C-T, and 2C-T-21 (2C-T-FE).
Alexander Shulgin attempted to synthesise this compound in the 1990s, and mentions it in his book PiHKAL (Phenethylamines I Have Known and Loved) under the entry for 2C-T-21, but was unsuccessful in producing a key intermediate and never assigned it a 2C-T number. This compound was ultimately first synthesised by Geoffrey Varty and colleagues at Irish biopharmaceutical company Helus Pharma (formerly Cybin) in 2023.
It has a K<sub>i</sub> of 0.35nM at the serotonin 5-HT<sub>2A</sub> receptor, and an of 4.1nM at the serotonin 5-HT<sub>2A</sub> receptor and 7.3nM at the serotonin 5-HT<sub>2C</sub> receptor, compared to 88nM at the serotonin 5-HT<sub>2B</sub> receptor. It is a potent, selective, long acting, and orally active agonist for the serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors and produces psychedelic-like responding in several different animal species. The interactions of 2C-T-36 with numerous other receptors and targets have also been described. It has only been studied preclinically as of 2024 and is not known to have been tested in humans.
It is a controlled substance in Canada under phenethylamine blanket-ban language. The drug is not an explicitly controlled substance in the United States.
Related drugs include the deuterated phenethylamine HLP005 (CYB005) and the deuterated substituted tryptamines HLP003 (CYB003) and HLP004 (CYB004).